References: Management of chronic hepatitis B: Antiviral therapy and monitoring

Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM). Viral Hepatitis Mapping Project: National Report 2018-19 (published 2020). Sydney: ASHM; 2019. https://www.ashm.org.au/programs/Viral-Hepatitis-Mapping-Project/
Bahr NC, Yarlagadda SG. Fanconi syndrome and tenofovir alafenamide: a case report. Ann Intern Med 2019;170(11):814–5. https://www.ncbi.nlm.nih.gov/pubmed/30690644
Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51(2):422–30. https://www.ncbi.nlm.nih.gov/pubmed/20049753
Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010;51(2):435–44. https://www.ncbi.nlm.nih.gov/pubmed/19918971
European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67(2):370–98. https://www.ncbi.nlm.nih.gov/pubmed/28427875
Fontana RJ. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol 2010;52(2):147–9. https://www.ncbi.nlm.nih.gov/pubmed/20006400
Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49(5 Suppl):S185–95. https://www.ncbi.nlm.nih.gov/pubmed/19399802
Hepatitis B Consensus Statement Working Group. Australian consensus recommendations for the management of hepatitis B infection. Melbourne: Gastroenterological Society of Australia; 2022. https://www.gesa.org.au/education/clinical-information/hbv-consensus-statement
Riches L, Cowie B, Nanver Z, Thomas L. Hepatitis B and immigration. Sydney: Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine; Last updated 29 January 2020. https://www.ashm.org.au/resources/HBV-Resources-list/hepatitis-b-and-immigration/
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015;385(9987):2606–15. https://www.ncbi.nlm.nih.gov/pubmed/25890673
Wong GL, Tse YK, Wong VW, Yip TC, Tsoi KK, Chan HL. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology 2015;62(3):684–93. https://www.ncbi.nlm.nih.gov/pubmed/25973979
World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: WHO; 2015. https://www.ncbi.nlm.nih.gov/pubmed/26225396